Product Information
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK is a brand product labeled by E.R. Squibb & Sons, L.L.C., priced at $5.5077 per EA under NDC 00003376474. Its NADAC has been published 433 times since Jun 20, 2018.
FDA first approved this application on Dec 28, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
E.R. Squibb & Sons, L.L.C.NDC
00003376474
Classification
Brand
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202155FDA Approved
12/28/2012
TE Code
AB
On Market Since
11/29/2017
Price Statistics
The NADAC for ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK has been published 433 times since Jun 20, 2018, and over the history we have for it it has declined 17.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $5.5077 per EA |
|---|---|
| All-time high | $9.6929 (May 14, 2025) |
| All-time low | $5.5059 (Jul 22, 2026) |
| 52-week high | $9.6685 |
| 52-week low | $5.5059 |
| Median price | $7.9900 |
| Average price | $8.0810 |
| Largest weekly change | -43.0% (Jan 14, 2026) |
| Weeks tracked | 433 |
| Tracking since | Jun 20, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the apixaban market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
E.R. Squibb & Sons, L.L.C. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
apixaban market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK?
The current National Average Drug Acquisition Cost (NADAC) for ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK, manufactured by E.R. Squibb & Sons, L.L.C., is $5.5077 per EA (NDC 00003376474), effective Sep 30, 2026.
How has the price of ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK changed over time?
Over the history we have for it, the NADAC for ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK has declined 17.7%. It has been tracked across 433 weekly CMS publications since Jun 20, 2018.
What are the highest and lowest recorded NADAC prices for ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK?
Since Jun 20, 2018, the NADAC for ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK has ranged from a low of $5.5059 (Jul 22, 2026) to a high of $9.6929 (May 14, 2025), with a median of $7.9900 per EA.
Are there cheaper alternatives to ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK?
No other NADAC-published product currently shares the active ingredient and strength of ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK?
ELIQUIS DVT-PE TREATMENT 30-DAY STARTER 5 MG PACK (NDC 00003376474) is labeled by E.R. Squibb & Sons, L.L.C., and CMS classifies it as a brand product.